Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) has issued an update.
Arovella Therapeutics has appointed Chief Operating Officer Dr Nicole Van Der Weerden as acting chief executive officer following the resignation and termination of former CEO Dr Michael Baker. Her remuneration has been lifted to match her predecessor’s, and the board plans to update the market on the ongoing search for a permanent chief executive.
The board highlighted Van Der Weerden’s leadership and existing executive team, noting she has already been steering strategic planning as the company advances towards a Phase I trial of its lead CAR-iNKT therapy, ALA-101. With extensive prior experience at Hexima in progressing drug candidates through pre-clinical and clinical development, her appointment is positioned as providing continuity and stability at a critical clinical inflection point for the company.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is an Australian biotechnology company focused on developing invariant natural killer T (iNKT) cell therapies for blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR-iNKT cell therapy targeting CD19-positive lymphomas and leukaemias, while ALA-105 is a CLDN18.2-directed, cytokine-armoured CAR-iNKT candidate for solid tumours.
Average Trading Volume: 909,114
Technical Sentiment Signal: Sell
Current Market Cap: A$84.61M
Find detailed analytics on ALA stock on TipRanks’ Stock Analysis page.